Unlocking the Earliest Stage of Alzheimer's Disease
Detection of the initiating factors of Alzheimer's Disease are critical for early diagnosis, effective disease management and therapeutic discovery. Today, the biomarker we rely on for early detection and therapeutic intervention (Amyloidβ) does not initiate the disease.
T-NeuroDx is commercializing a test that detects a biomarker - hiT cells - that is the first identified initiating factor of Alzheimer's. hiT cells have huge potential to add sensitivity and earlier disease detection capabilities to existing biomarker panels and enable the development of a new class of therapeutics.
Based on Paradigm-Shifting Research
Research led by our Co-Founder and Chief Science Officer, Dr. Christopher Wheeler, identified aged, self-reactive T cells in the brains of Alzheimer’s patients.
As published in Panwar et al., 2024, this research demonstrated that these T cells not only migrate from peripheral blood to the brain early in the disease, but also initiate comprehensive Alzheimer's pathology in mice.
This is the first time a biomarker has been shown to initiate Alzheimer's in an animal model and to identify early stages of the disease in humans.
Aged, Self-Reactive T Cells are an Initiating Factor and Early Detection Biomarker
